Levodopa therapy monitoring in patients with Parkinson disease: A kinetic-dynamic approach

Therapeutic Drug Monitoring

Volumn 23, Issue 6, 2001, Pages 621-629

  Contin, M ^a   Riva, R ^a   Martinelli, P ^a   Albani, F ^a   Avoni, P ^a   Baruzzi, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Kinetic dynamic modeling; Levodopa; Parkinson disease; Therapeutic drug monitoring

Indexed keywords

AMANTADINE; BROMOCRIPTINE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ADULT; AGED; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESPONSE; DYSKINESIA; FEMALE; FINGER; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL; MOTOR ACTIVITY; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; ANTIPARKINSON AGENTS; DRUG MONITORING; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MOTOR ACTIVITY; PARKINSON DISEASE;

EID: 0035178815     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200112000-00005     Document Type: Article

References (28)

1. Parkinson's disease
2. On-off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics
3. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II
4. L-3-4-dihydroxyphenylalanineinduced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: Differential effects of monoamine oxidase A and B inhibitors
5. A hypothesis on the pathophysiologic mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment
6. Episodic unresponsiveness to single doses of 1-dopa in parkinsonian fluctuators
7. Pharmacokinetic optimisation in the treatment of Parkinson's disease
8. Response to a standard oral levodopa test in Parkinsonian patients with and without motor fluctuations
9. Pharmacodynamic modeling of oral levodopa: Clinical application in Parkinson's disease
10. Parkinsonism: Onset, progression and mortality
11. The relevance of the Lewy body to pathogenesis of idiopathic Parkinson's disease
12. Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter- and intrarater reliability assessment
13. Simple and rapid micromethod for the determination of levodopa and 3-O-methyldopa in human plasma by high-performance liquid chromatography with coulometric detection
14. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine
15. Methodological issues in pharmacokinetic-pharmacodynamic modeling
16. IGPHARM: Interactive graphic package for pharmacokinetic analysis
17. Methods for finding the minimum of a function of several variables without calculating derivatives
18. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model
19. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease
20. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease
21. The response to levodopa in Parkinson's disease: Imposing pharmacological law and order
22. A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease
23. Concentration-effect relationship of levodopa in patients with Parkinson's disease
24. Effect of long-term therapy on the pharmacodynamics of levodopa: Relation to on-off phenomenon
25. Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: A 3-year follow-up study
26. Pharmacokinetic and pharmacodynamic modeling of L-Dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet
27. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients
28. Critical issues in therapeutic drug monitoring: Pathways to the future